Cargando…
Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial (Diabetes Metab J 2023;47:668-81)
Autores principales: | Scherbak, Nikolai N., Kruse, Robert, Nyström, Thomas, Jendle, Johan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Diabetes Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10695721/ http://dx.doi.org/10.4093/dmj.2023.0355 |
Ejemplares similares
-
Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial (Diabetes Metab J 2023;47:668-81)
por: Lee, Da Young
Publicado: (2023) -
Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial
por: Scherbak, Nikolai N., et al.
Publicado: (2023) -
FAIM Is Regulated by MiR-206, MiR-1-3p and MiR-133b
por: Coccia, Elena, et al.
Publicado: (2020) -
miR766-3p and miR124-3p Dictate Drug Resistance and Clinical Outcome in HNSCC
por: Shibata, Tomohiro, et al.
Publicado: (2022) -
Expression of miR-1, miR-133a, miR-133b and miR-206 increases during development of human skeletal muscle
por: Koutsoulidou, Andrie, et al.
Publicado: (2011)